Shots:
- P-II neoadj. studies were UNICORN (n=56) & NEST (n=24) in resectable CRC. UNICORN: 93% & 29% pCR with 100% & 36% pMR in dMMR/MSI-H & pMMR/MSS tumors, respectively; NEST: At 18 (NEST-1) & 9mos. (NEST-2) follow-up, all were ctDNA-ve w/o recurrences; pMR improved to 47% in MSS tumors in NEST-2
- P-I/II study of BOT/BAL with FOLFOX-Avastin in 1L MSS mCRC showed 71% ORR in 14 pts (12 treated with FOLFOX) & 67% in those with liver metastases
- Global P-II trial of BOT/BAL (75/150mg) in refractory MSS mCRC pts (n=234). 75mg depicted 19% ORR, 55% DCR & durable responses (70% ongoing at data cut-off) & will enter P-III. Another P-II trial of BOT/BAL/AgenT-797 with Cyramza & paclitaxel showed early activity in 2L metastatic GE cancers; data expected in H2’25
Ref: Businesswire | Image: Agenus
Related News:- Tris Pharma Reports the P-III (ALLEVIATE-1) Study Results of Cebranopadol to Treat Moderate-to-Severe Acute Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
